Gains May Be On The Menu For Recursion Pharmaceuticals Inc (NASDAQ: RXRX)
Currently, there are 399.15M common shares owned by the public and among those 310.65M shares have been available to trade. The company’s stock has a 5-day price change of 0.00% and -15.75% over the past three months. RXRX shares are trading -46.38% year to date (YTD), with the 12-month market performance down to -25.59% lower. […]
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Seen Running Too Hot, Let’s Look At This More Closely
Currently, there are 399.15M common shares owned by the public and among those 310.78M shares have been available to trade. The company’s stock has a 5-day price change of -2.71% and -22.38% over the past three months. RXRX shares are trading -46.32% year to date (YTD), with the 12-month market performance down to -25.59% lower. […]
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Is Getting Increasingly Hard To Ignore
Currently, there are 399.15M common shares owned by the public and among those 310.78M shares have been available to trade. The company’s stock has a 5-day price change of -10.38% and -22.52% over the past three months. RXRX shares are trading -27.22% year to date (YTD), with the 12-month market performance down to -42.66% lower. […]
Value Hunters: Look To Recursion Pharmaceuticals Inc (RXRX)
Currently, there are 399.15M common shares owned by the public and among those 310.78M shares have been available to trade. The company’s stock has a 5-day price change of 31.34% and -16.69% over the past three months. RXRX shares are trading -18.79% year to date (YTD), with the 12-month market performance down to -34.72% lower. […]
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Hogging The Spotlight Today
Currently, there are 399.15M common shares owned by the public and among those 310.78M shares have been available to trade. The company’s stock has a 5-day price change of 0.84% and -44.34% over the past three months. RXRX shares are trading -38.17% year to date (YTD), with the 12-month market performance down to -53.50% lower. […]
Reviewing The Case For Recursion Pharmaceuticals Inc (RXRX) Going Higher
Currently, there are 399.15M common shares owned by the public and among those 310.78M shares have been available to trade. The company’s stock has a 5-day price change of -2.66% and -46.07% over the past three months. RXRX shares are trading -35.06% year to date (YTD), with the 12-month market performance down to -53.10% lower. […]
Recursion Pharmaceuticals Inc (RXRX) Testing Investors’ Patience Right Now
Currently, there are 183.21M common shares owned by the public and among those 146.52M shares have been available to trade. Insiders at the company have transacted a total of 136 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 56 of these insider trades were purchases, […]
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) – Suitable For Long Term Buy?
Currently, there are 183.21M common shares owned by the public and among those 151.91M shares have been available to trade. Insiders at the company have transacted a total of 143 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 61 of these insider trades were purchases, […]
Now Is A Suitable Moment For A Long-Term Purchase Of Recursion Pharmaceuticals Inc (NASDAQ: RXRX)
Currently, there are 183.21M common shares owned by the public and among those 151.89M shares have been available to trade. Insiders at the company have transacted a total of 153 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 65 of these insider trades were purchases, […]
Recursion Pharmaceuticals Inc (NASDAQ: RXRX): Reassessing Prospects
Recursion Pharmaceuticals Inc (RXRX) concluded trading on Thursday at a closing price of $9.90, with 4.24 million shares of worth about $41.99 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -9.75% during that period and on Thursday the price saw a gain of […]